ClinicalTrials.gg
Not yet recruitingNCT07818616Updated Sep 16, 2026

Electromyography Biofeedback Training Versus Mirror Therapy on Muscle Activity, Range of Motion and Function of Upper Limb in Children With Hemiplegia

An interventional study of Neurotrac Simplex electromyography biofeedback device and Mirror in Hemiplegic Cerebral Palsy, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 8 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
8 Years to 12 Years
Sex
All
01

Study summary

One of the main motor control issues in hemiplegic CP is spasticity, which affects the flexor muscles of the upper limb. This spasticity causes the limb to adopt a flexed posture, limiting the range of motion and contributing to a decreased ability to perform tasks that require precise movement and controlled muscle activation. Several studies have demonstrated that EMG biofeedback can significantly improve upper limb function in children with hemiplegic CP. Also, mirror therapy has gained recognition as an innovative and effective rehabilitation method for children with hemiplegic CP

Read the detailed description

Ethics statement:

The current study was approved by the local Ethical Committee at the Faculty of Physical Therapy Cairo University (No: P.T.REC/012/005590).

Study Design:

Comparative randomized study.

Sample size estimation Sample size calculation was done using the comparison of QUEST scale as a marker for upper limb functional performance between children with hemiplegic cerebral palsy treated with electromyography biofeedback training and those treated with mirror therapy. As reported in a previous publication, the mean ± SD of length of QUEST scale in Smart Glove group was 328 ± 52, while in conventional group it was 265.4 ± 45.5. Accordingly, we calculated that the minimum proper sample size was 18 participants in each group to be able to reject the null hypothesis with 80% power at α = 0.05 level using Student's t test for independent samples. Sample size calculation was done using PS Power and Sample Size Calculations Software, version 3.1.2 for MS Windows (William D. Dupont and Walton D., Vanderbilt University, Nashville, Tennessee, USA).

Randomization Forty hemiplegic children will be randomly assigned into two equal groups; group A and group B. The way of randomization will be using sealed envelopes; each envelope contains a sheet of paper that will show where the child will be assigned; either into group A or group B. The process of randomization will be performed by an independent person who will be blinded to the purpose or protocol of the study.

02

Conditions studied

  • Hemiplegic Cerebral Palsy

Keywords

  • Cerebral palsy
  • Hemiplegia
  • Mirror therapy
  • EMG biofeedback
03

In context

Cerebral Palsy

1,936 studies on the registry are indexed under Cerebral Palsy; 458 are open to participants now.

This study's planned enrollment of 40 is above the median of 34 across 1,431 interventional studies indexed under Cerebral Palsy.

Browse Cerebral Palsy studies →

Lead sponsor

Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ranging from 8 to 12 years
  • Spasticity grade 1+ and 2 on the Modified Ashworth Scale
  • Gross Motor Function Classification System (GMFCS) level I or II
  • Ability to follow verbal instructions

Exclusion criteria

Exclusion Criteria:

  • Visual or hearing defects
  • Neurological conditions other than cerebral palsy
  • Previous surgical intervention of the upper limb
  • Botulinum toxin injection into the upper limb within the last 6 months prior to the study
  • Fractures of the upper limb
  • Uncontrolled convulsions
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    EMG Biofeedback Training

    Children in group A will receive 30 minutes of EMG biofeedback training. The EMG biofeedback device will be placed on the muscles of the upper extremities. First, surface electrodes will be applied at the deltoid muscle for 10 minutes; then electrodes will be applied at the triceps for 10 minutes, and then electrodes will be applied at the wrist extensors for 10 minutes to pick up the activity of the muscles and convert it to visual and auditory impulses produced from the device. In addition to the designed physical therapy program for 30 minutes

    Device: Neurotrac Simplex electromyography biofeedback device · Other: a designed physical therapy program

  • Experimental
    Mirror Therapy Training

    Children in group B will receive 30 minutes of mirror therapy training. Children will be seated on a chair, with the mirror positioned between the upper limbs perpendicular to the child's midline, and the reflecting side of the mirror will be adjusted to face the non-affected arm. Isolated movements of shoulder, elbow, and wrist joints by the unaffected limb will be performed in all degrees of freedom. In each direction up to 30 repetitions per session. In addition to the same designed physical therapy program for 30 minutes as group A.

    Other: Mirror · Other: a designed physical therapy program

Interventions

  • DeviceNeurotrac Simplex electromyography biofeedback device

    This intervention has been assigned to 'Group A.'. The Neurotrac Simplex device has been developed to enhance the understanding of muscle activity and to improve muscle conditioning. It stands upright on a flat surface, enabling the user to carry out specific exercises and at the same time view the biofeedback by way of bright LED lights on the front of the unit; the LCD screen will automatically display the average muscle readings for the session. Then using training programs in the NeuroTrac software for facilitation of the desired muscle. This software will be used in training the program for group A.

  • OtherMirror

    This intervention has been assigned to 'Group B.'A mirror (20 cm × 70 cm) on a movable stand will be used to provide a mirror therapy training program for group B. It stands on mobile wheels surrounded by a frame made of wood, with the main reflective surface likely being a standard glass mirror. The affected limb will be situated in a safe and preferably comfortable position behind the mirror. The non-affected limb will be positioned in a similar position as the affected limb, which would result in facilitating the intensity of the mirror illusion. The therapist will repeatedly remind the child to focus on the movement of the unaffected limb in front of the mirror, which helped to increase the mirror illusion. Under the supervision of the physiotherapist, children observed the reflection of their unaffected limb while performing the following movement: flexion of the shoulder, elbow extension, and wrist extension.

  • Othera designed physical therapy program

    This intervention has been assigned to both groups. A designed physical therapy program for 30 minutes three times per week for three successive months 1. Active resisted exercises: A. Shoulder flexion and abduction. B. Elbow extension. C. Wrist extension. 2. Hand weight-bearing exercises: A. Quadriped position B. Side-sitting position C. Hand support standing 3. Reaching exercise with shoulder flexion, elbow and wrist extended. 4. Throwing the ball overhead by the affected hand and by both hands. 5. Protective extensor thrust from sitting on the roll and from the standing position. 6. Wheelbarrow walking (walking on hands).

06

What researchers measure

Primary outcomes

  1. muscle activity of deltoid, elbow extensor, and wrist extensor muscles

    The Neurotrac Simplex EMG biofeedback device (model ESS102, manufactured by Verity Medical Ltd., UK) is a single-channel EMG device that has been designed to be used with a variety of applications. It acts as a diagnostic tool to measure the muscle activity, which is measured in microvolts (μV). The Neurotrac Simplex is an accurate and sensitive device that measures muscle activity down to as low as 0.2 μV and up to 2000 μV. The diverse range enables the device to measure very weak muscle activity

    Time frame: The treatment period will be 3 times per week for 3 successive months

  2. ROM of shoulder, elbow, and wrist joints

    A goniometer is an instrument that either measures an angle or allows an object to be rotated to a precise angular position. The baseline digital goniometer is used to measure a patient's ROM and incorporates integral absolute vertical and horizontal levels in one arm for ease of use. The device weighs 0.45 kg. The device displays 0 to 180 degrees on an LCD screen for viewing readings and has the ability to freeze angle measurements for reference. The goniometer has a durable powder-coated steel exterior with inch/cm marks screened onto its arms and is powered by one 9V battery (included). (L is length, the horizontal distance from left to right; W is width, the horizontal distance from front to back; H is height, the vertical distance from the lowest to highest point.) These ROM measurements can be taken at any joint, and they typically involve some knowledge about the anatomy of the body, particularly bony landmarks

    Time frame: The treatment period will be 3 times per week for 3 successive months

  3. quality of upper limb movement

    The Quality of Upper Extremity Skills Test is a descriptive, impairment-based, and evaluative measure designed to evaluate movement patterns and hand function in CP children separately for each arm. It has been validated for children who exhibit neuromotor dysfunction with spasticity. Quality of movement is assessed in four domains: dissociated movements (19 items), grasp (6 items), weight bearing (5 items), and protective extension (3 items), including 33 items. The total testing time, including administration and scoring, is approximately 45 minutes

    Time frame: The treatment period will be 3 times per week for 3 successive months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07818616
Lead sponsor
Cairo University
Responsible party
Andrew Gameel Mourice (Principal Investigator, Cairo University) — Principal investigator
First posted
Sep 14, 2026
Start date
Sep 10, 2026 (estimated)
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 16, 2026

Study contacts

Andrew G Mourice
Contact
drandrewgameel1@gmail.com
01278280393
Hebatallah M Kamal
study chair · Cairo University, Egypt
Hala R Mahmoud
study director · Cairo University, Egypt
Walaa A Abd El-Nabie
study director · Cairo University, Egypt
Andrew G Mourice
principal investigator · Cairo University, Egypt

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion